

# **IVUS for Complex PCI: Secret Pearls from the Expert**

**Myeong-Ki Hong, MD. PhD**

**Professor of Medicine**

**Cardiology Division, Severance Cardiovascular Hospital  
Yonsei University College of Medicine, Seoul, Korea**

# Conflict of Interest


- I have nothing to disclose

# Benefits from IVUS-guided PCI

- **Left main**
- **Bifurcation**
- **Diffuse long lesion**
- **Calcified lesion**
- **Chronic total occlusion**
- **Chronic kidney disease**


# ADAPT-DES substudy (n=8,583 pts, IVUS=3,349 pts and no IVUS=5,234 pts)

## Definite/Probable Stent Thrombosis



Number at risk:					
IVUS Use	3349	3251	3221	3197	3023
No IVUS Use	5234	5015	4978	4938	4585

## MI




Number at risk:					
IVUS Use	3349	3209	3171	3141	2969
No IVUS Use	5234	4932	4882	4830	4460

**IVUS guidance during DES PCI may result in less stent thrombosis as well as fewer myocardial infarctions and MACEs**

Witzenbichler B, et al. *Circulation* 2014;129: 463-470

# MAIN-COMPARE registry: 3-year mortality (145 propensity matched pairs)

Park SJ et al, *Circ Cardiovasc Intervent.* 2009;2:167-177




Patients at risk

IVUS-guidance	145	140	98	37
Angiography-guidance	145	137	88	29

# Impact of IVUS-Guidance on 3-Year Clinical Outcomes: DES for Bifurcation Lesions from a Korean multi-center bifurcation registry

(487 propensity matched pairs)



Patients at risk

IVUS-guidance

487

467

281

118

Angiography-guidance

487

469

346

124

Kim JS, Hong MK, et al. *Am Heart J* 2011;161:180-187

# 2014 ESC/EACTS Guidelines on myocardial revascularization


Recommendations	Class <sup>a</sup>	Level <sup>b</sup>	Ref. <sup>c</sup>
FFR to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available.	I	A	
FFR-guided PCI in patients with multivessel disease.	IIa	B	
IVUS in selected patients to optimize stent implantation.	IIa	B	702,703,706
IVUS to assess severity and optimize treatment of unprotected left main lesions.	IIa	B	705
IVUS or OCT to assess mechanisms of stent failure.	IIa	C	
OCT in selected patients to optimize stent implantation.	IIb	C	

Level of Evidence is B

# Clinical usefulness of IVUS, 2014




**IVUS usage  
during PCI**



**Improved  
clinical  
outcomes**





# Chronic total occlusion: CTO-IVUS randomized trial



Kim BK, Jang Y et al, *Circ Cardiovasc Interv.* 2015;8:e002592

# Diffuse long lesion: IVUS-XPL randomized trial

MACE: Cardiac death, MI, or TLR at 1 year




Hong SJ, Hong MK (corresponding author), et al. *JAMA* 2015;314:2155-63

# Meta-analysis of 7 randomized trials: IVUS vs. angio-guided (first and next-generation) DES implantation

Event: cardiac death, MI, TLR

Study-level meta-analysis

Study	Year
IVUS-XPL	2015
CTO-IVUS	2015
AIR-CTO	2015
Tan et al	2015
Kim et al (RESET)	2013
AVIO	2013
HOME DES IVUS	2010
<b>Overall</b>	



OR	Events: IVUS	Events: Angio
0.49	19/700	39/700
0.37	5/201	14/201
0.82	25/115	29/115
0.42	8/61	17/62
0.60	12/269	20/274
0.67	24/142	33/142
0.91	11/105	12/105
<b>0.60</b>	<b>104/1593</b>	<b>164/1599</b>

**IVUS better Angio better**

Islam Y. Elgendy et al. *Circ Cardiovasc Interv.* 2016;9:e003700



# IVUS-XPL: Randomized Trial


	IVUS-guidance (n=700)	Angiography-guidance (n=700)	Hazard ratio (95% CI)	Log-Rank P value
<b>Primary End Point</b>				
<b>MACE</b>	19 (2.9%)	39 (5.8%)	0.48 (0.28–0.83)	.007
<b>Secondary End Point</b>				
Cardiac death	3 (0.4%)	5 (0.7%)	0.60 (0.14-2.52)	.48
Target lesion related MI	0	1 (0.1%)	-	.32
<b>Ischemia-driven TLR</b>	17 (2.5%)	33 (5.0%)	0.51 (0.28-0.91)	.02
Stent thrombosis	2 (0.3%)	2 (0.3%)	1.00 (0.14-7.10)	1.00
Acute	1 (0.1%)	1 (0.1%)	-	-
Sub-acute	1 (0.1%)	0	-	-
Late	0	1 (0.1%)	-	-

Hong SJ, Kim BK, Hong MK, et al. JAMA 2015;314:2155-63


# Meta-analysis with Individual Patient-Level Data from 2,345 Randomized Patients with second-generation DES (RESET Long, CTO IVUS and IVUS XPL)

Hard events of MACE (cardiac death, MI, or stent thrombosis)

## Intention-to treat analysis




## Per-protocol analysis



Shin DH, Hong MK (corresponding author), et al. *JACC Intv* 2016;9:2232-2239

# How the IVUS information influenced the procedure? From ADAPT-DES Study


When IVUS was used, the operator was required to report the timing of IVUS imaging (eg, before intervention, after DES, after adjunct balloon inflation) and how the IVUS information influenced the procedure.



Witzenbichler B et al. Circulation. 2014;129:463-470

# From ILUMEIN I Study

- OCT impacted on PCI procedure in **65% of pts** either pre-PCI and/or post-PCI



- Post-PCI FFR** values were significantly different between optimization groups (lower in cases with pre- and post-PCI reaction to OCT) but no longer different after post-PCI stent optimization.
- MACE events at 30 days** were low: death 0.25%, MI 7.7%, repeat PCI 1.7%, and stent thrombosis 0.25%

# 2018 European expert consensus documents

**Table 2** Recommendations on the adjunctive use of intravascular imaging for diagnostic evaluation of coronary artery disease, guidance and optimization of PCIs

- **Diagnostic assessment of coronary lesions**

**Consensus opinion**

Angiographically unclear/ambiguous findings (e.g. dissection, thrombus, calcified nodule)

Assessment of left main stenosis

Complex bifurcation lesions

Suspected culprit lesion of ACS

- **PCI guidance and optimization**

**RCT evidence**

Long lesions

Chronic total occlusions

**Consensus opinion**

Patients with acute coronary syndromes

Left main coronary artery lesions

Two stents bifurcation

Implantation of bioresorbable scaffolds

Patients with renal dysfunction (IVUS)

- **Identification of mechanism of stent failure**

Restenosis

Stent thrombosis

*Eur Heart J* 2018;39:3281-3300



# 2018 ESC/EACTS Guidelines on myocardial revascularization

## Recommendations on intravascular imaging for procedural optimization

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
IVUS or OCT should be considered in selected patients to optimize stent implantation. <sup>603,612,651–653</sup>	IIa	B
IVUS should be considered to optimize treatment of unprotected left main lesions. <sup>35</sup>	IIa	B

© ESC 2018

IVUS = intravascular ultrasound; OCT = optical coherence tomography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

*Eur Heart J* 2018 (in press)

## 2014 ESC/EACTS Guidelines

## 2018 ESC/EACTS Guidelines

IVUS in selected patients to optimize stent implantation.	<b>IIa</b>	<b>B</b>
IVUS to assess severity and optimize treatment of unprotected left main lesions.	<b>IIa</b>	<b>B</b>
IVUS or OCT to assess mechanisms of stent failure.	<b>IIa</b>	<b>C</b>

### Recommendations on intravascular imaging for procedural optimization

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
IVUS or OCT should be considered in selected patients to optimize stent implantation. <sup>603,612,651–653</sup>	<b>IIa</b>	<b>B</b>
IVUS should be considered to optimize treatment of unprotected left main lesions. <sup>35</sup>	<b>IIa</b>	<b>B</b>

© ESC 2018

IVUS = intravascular ultrasound; OCT = optical coherence tomography.

<sup>a</sup>Class of recommendation.

<sup>b</sup>Level of evidence.

**No change of recommendation to use IVUS in guideline**

# Secret Pearls

**Just do IVUS in PCI for  
complex lesions.**

# Dreams will come true

